Treatment of Cytomegalovirus Encephalitis in Pregnancy
Cytomegalovirus encephalitis presenting during pregnancy requires careful antiviral management and close multidisciplinary coordination. The pregnant context introduces specific considerations that shape both agent selection and the level of specialist involvement required.
Clinical Scenario
During pregnancy, the indications for treating CMV encephalitis follow the same clinical framework as for non-pregnant patients in this population. However, pregnancy itself directly influences which therapeutic options can be used and mandates involvement of a maternal–fetal medicine specialist in certain treatment decisions.
Treatment Approach (Overview)
Antiviral therapy is the foundation of management. When the primary antiviral approach is not viable due to resistance or tolerability, alternative agents exist — but their use in pregnancy requires direct consultation with a maternal–fetal medicine specialist and may prompt additional fetal surveillance.
The complete regimen, specific agent selection criteria, and full monitoring recommendations are available in the structured protocol.
References
During pregnancy, indications for treatment of CMV infection are the same as for other people with HIV (AIII).
Foscarnet and cidofovir are not recommended in the absence of resistance or toxicity with ganciclovir/valganciclovir (AIII); use of foscarnet and cidofovir should only be done in consultation with a maternal–fetal medicine specialist, and additional fetal surveillance may be recommended in the setting of maternal renal insufficiency (BIII).